ropinirole

General information

• Class: Adjunctive therapy
• Common US brands: Requip
• Therapeutic drug monitoring not routinely recommended.
• Last reviewed: 2025-12-30

Dosing & forms

• Forms/strengths: —
• Frequency: —
• Food: —
• Typical range: —

Mechanism (brief)

Non-ergoline dopamine agonist (D2/D3) indicated for Parkinson’s disease and moderate-to-severe primary restless legs syndrome; metabolized primarily by CYP1A2 with ~6 hour half-life and clinically important somnolence, impulse- control, hallucination/psychosis, and RLS augmentation considerations.

Metabolism & Half‑life

• Metabolism: CYP1A2 (major)
• Half‑life: Single-dose mean 6 h

Therapeutic Drug Monitoring (TDM)

Recommended: No

Monitoring highlights

• —

Sources

• Ropinirole tablets prescribing information — DailyMed (2025)
• Treatment of restless legs syndrome and periodic limb movement disorder: an American Academy of Sleep Medicine clinical practice guideline — Journal of Clinical Sleep Medicine (2025)
• The Management of Restless Legs Syndrome: An Updated Algorithm — Mayo Clinic Proceedings (2021)
• Randomized, double-blind, placebo-controlled, short-term trial of ropinirole in restless legs syndrome — Sleep Medicine (2005)